Review article: Permanent drug withdrawal is desirable and achievable for autoimmune hepatitis

Alimentary Pharmacology and Therapeutics

Volumn 39, Issue 10, 2014, Pages 1043-1058

  Czaja, A J ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; AZATHIOPRINE; CHEMOKINE RECEPTOR CX3CR1; CHEMOKINE RECEPTOR CXCR3; CHEMOKINE RECEPTOR CXCR4; CXCL11 CHEMOKINE; CXCL9 CHEMOKINE; FRACTALKINE; MACROPHAGE INFLAMMATORY PROTEIN 3ALPHA; STROMAL CELL DERIVED FACTOR 1;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; APOPTOSIS; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; AUTOIMMUNE HEPATITIS; BONE MARROW SUPPRESSION; DISEASE ASSOCIATION; DRUG DEPENDENCE TREATMENT; DRUG DOSE REDUCTION; DRUG HYPERSENSITIVITY; DRUG WITHDRAWAL; EPSTEIN BARR VIRUS; HEPATITIS A VIRUS; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HUMAN; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; LIVER CELL; LIVER CIRRHOSIS; LIVER INJURY; LONG TERM CARE; MEASLES VIRUS; MOLECULAR MIMICRY; NEUTROPHIL CHEMOTAXIS; PRIORITY JOURNAL; RELAPSE; REMISSION; REVIEW; RISK FACTOR; STANDARDIZED INCIDENCE RATIO; SYSTEMATIC REVIEW; TREATMENT OUTCOME; TREATMENT WITHDRAWAL;

FEMALE; GLUCOCORTICOIDS; HEPATITIS, AUTOIMMUNE; HUMANS; LIVER CIRRHOSIS; LIVER FUNCTION TESTS; MALE; RECURRENCE; TREATMENT OUTCOME;

EID: 84899075306     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.12701     Document Type: Review

References (171)

1. Cook GC, Mulligan R, Sherlock S,. Controlled prospective trial of corticosteroid therapy in active chronic hepatitis. Q J Med 1971; 40: 159-85.
2. Soloway RD, Summerskill WH, Baggenstoss AH, et al,. Clinical, biochemical, and histological remission of severe chronic active liver disease: a controlled study of treatments and early prognosis. Gastroenterology 1972; 63: 820-33.
3. Murray-Lyon IM, Stern RB, Williams R,. Controlled trial of prednisone and azathioprine in active chronic hepatitis. Lancet 1973; 1: 735-7.
4. Verma S, Gunuwan B, Mendler M, et al,. Factors predicting relapse and poor outcome in type I autoimmune hepatitis: role of cirrhosis development, patterns of transaminases during remission and plasma cell activity in the liver biopsy. Am J Gastroenterol 2004; 99: 1510-6.
5. Miyake Y, Iwasaki Y, Terada R, et al,. Persistent normalization of serum alanine aminotransferase levels improves the prognosis of type 1 autoimmune hepatitis. J Hepatol 2005; 43: 951-7.
6. Montano-Loza AJ, Carpenter HA, Czaja AJ,. Improving the end point of corticosteroid therapy in type 1 autoimmune hepatitis to reduce the frequency of relapse. Am J Gastroenterol 2007; 102: 1005-12.
7. Czaja AJ, Davis GL, Ludwig J, et al,. Complete resolution of inflammatory activity following corticosteroid treatment of HBsAg-negative chronic active hepatitis. Hepatology 1984; 4: 622-7.
8. Roberts SK, Therneau TM, Czaja AJ,. Prognosis of histological cirrhosis in type 1 autoimmune hepatitis. Gastroenterology 1996; 110: 848-57.
9. Floreani A, Niro G, Rosa Rizzotto E, et al,. Type I autoimmune hepatitis: clinical course and outcome in an Italian multicentre study. Aliment Pharmacol Ther 2006; 24: 1051-7.
10. Seo S, Toutounjian R, Conrad A, et al,. Favorable outcomes of autoimmune hepatitis in a community clinic setting. J Gastroenterol Hepatol 2008; 23: 1410-4.
11. Hoeroldt B, McFarlane E, Dube A, et al,. Long-term outcomes of patients with autoimmune hepatitis managed at a nontransplant center. Gastroenterology 2011; 140: 1980-9.
12. Schvarcz R, Glaumann H, Weiland O,. Survival and histological resolution of fibrosis in patients with autoimmune chronic active hepatitis. J Hepatol 1993; 18: 15-23.
13. Dufour JF, DeLellis R, Kaplan MM,. Reversibility of hepatic fibrosis in autoimmune hepatitis. Ann Intern Med 1997; 127: 981-5.
14. Cotler SJ, Jakate S, Jensen DM,. Resolution of cirrhosis in autoimmune hepatitis with corticosteroid therapy. J Clin Gastroenterol 2001; 32: 428-30.
15. Czaja AJ, Carpenter HA,. Decreased fibrosis during corticosteroid therapy of autoimmune hepatitis. J Hepatol 2004; 40: 646-52.
16. Mohamadnejad M, Malekzadeh R, Nasseri-Moghaddam S, et al,. Impact of immunosuppressive treatment on liver fibrosis in autoimmune hepatitis. Dig Dis Sci 2005; 50: 547-51.
17. Zachou K, Gatselis N, Papadamou G, et al,. Mycophenolate for the treatment of autoimmune hepatitis: prospective assessment of its efficacy and safety for induction and maintenance of remission in a large cohort of treatment-naive patients. J Hepatol 2011; 55: 636-46.
18. Manns MP, Woynarowski M, Kreisel W, et al,. Budesonide induces remission more effectively than prednisone in a controlled trial of patients with autoimmune hepatitis. Gastroenterology 2010; 139: 1198-206.
19. Czaja AJ,. Emerging opportunities for site-specific molecular and cellular interventions in autoimmune hepatitis. Dig Dis Sci 2010; 55: 2712-26.
20. Czaja AJ,. Nonstandard drugs and feasible new interventions for autoimmune hepatitis. Part- I. Inflamm Allergy Drug Targets 2012; 11: 337-50.
21. Czaja AJ,. Nonstandard drugs and feasible new interventions for autoimmune hepatitis. Part-II. Inflamm Allergy Drug Targets 2012; 11: 351-63.
22. Czaja AJ,. Autoimmune hepatitis. Part A: pathogenesis. Expert Rev. Gastroenterol Hepatol 2007; 1: 113-28.
23. Czaja AJ,. Genetic factors affecting the occurrence, clinical phenotype, and outcome of autoimmune hepatitis. Clin Gastroenterol Hepatol 2008; 6: 379-88.
24. Vergani D, Mieli-Vergani G,. Aetiopathogenesis of autoimmune hepatitis. World J Gastroenterol 2008; 14: 3306-12.
25. Czaja AJ, Ammon HV, Summerskill WH,. Clinical features and prognosis of severe chronic active liver disease (CALD) after corticosteroid-induced remission. Gastroenterology 1980; 78: 518-23.
26. Czaja AJ, Ludwig J, Baggenstoss AH, et al,. Corticosteroid-treated chronic active hepatitis in remission: uncertain prognosis of chronic persistent hepatitis. N Engl J Med 1981; 304: 5-9.
27. Hegarty JE, Nouri Aria KT, Portmann B, et al,. Relapse following treatment withdrawal in patients with autoimmune chronic active hepatitis. Hepatology 1983; 3: 685-9.
28. Czaja AJ, Menon KV, Carpenter HA,. Sustained remission after corticosteroid therapy for type 1 autoimmune hepatitis: a retrospective analysis. Hepatology 2002; 35: 890-7.
29. Johnson PJ, McFarlane IG, Williams R,. Azathioprine for long-term maintenance of remission in autoimmune hepatitis. N Engl J Med 1995; 333: 958-63.
30. Seela S, Sheela H, Boyer JL,. Autoimmune hepatitis type 1: safety and efficacy of prolonged medical therapy. Liver Int 2005; 25: 734-9.
31. Czaja AJ,. Late relapse of type 1 autoimmune hepatitis after corticosteroid withdrawal. Dig Dis Sci 2010; 55: 1761-9.
32. van Gerven NM, Verwer BJ, Witte BI, et al,. Relapse is almost universal after withdrawal of immunosuppressive medication in patients with autoimmune hepatitis in remission. J Hepatol 2013; 58: 141-7.
33. Czaja AJ,. Safety issues in the management of autoimmune hepatitis. Expert Opin Drug Saf 2008; 7: 319-33.
34. Czaja AJ,. Features and consequences of untreated type 1 autoimmune hepatitis. Liver Int 2009; 29: 816-23.
35. Czaja AJ, Beaver SJ, Shiels MT,. Sustained remission after corticosteroid therapy of severe hepatitis B surface antigen-negative chronic active hepatitis. Gastroenterology 1987; 92: 215-9.
36. Wang KK, Czaja AJ, Beaver SJ, et al,. Extrahepatic malignancy following long-term immunosuppressive therapy of severe hepatitis B surface antigen-negative chronic active hepatitis. Hepatology 1989; 10: 39-43.
37. Ngu JH, Gearry RB, Frampton CM, et al,. Mortality and the risk of malignancy in autoimmune liver diseases: a population-based study in Canterbury, New Zealand. Hepatology 2012; 55: 522-9.
38. Czaja AJ,. Hepatocellular cancer and other malignancies in autoimmune hepatitis. Dig Dis Sci 2013; 58: 1459-76.
39. Langagergaard V, Pedersen L, Gislum M, et al,. Birth outcome in women treated with azathioprine or mercaptopurine during pregnancy: a Danish nationwide cohort study. Aliment Pharmacol Ther 2007; 25: 73-81.
40. Cleary BJ, Kallen B,. Early pregnancy azathioprine use and pregnancy outcomes. Birth Defects Res A Clin Mol Teratol 2009; 85: 647-54.
41. Frei P, Biedermann L, Nielsen OH, et al,. Use of thiopurines in inflammatory bowel disease. World J Gastroenterol 2013; 19: 1040-8.
42. Montano-Loza AJ, Carpenter HA, Czaja AJ,. Consequences of treatment withdrawal in type 1 autoimmune hepatitis. Liver Int 2007; 27: 507-15.
43. Czaja AJ,. Low-dose corticosteroid therapy after multiple relapses of severe HBsAg-negative chronic active hepatitis. Hepatology 1990; 11: 1044-9.
44. Kanzler S, Gerken G, Lohr H, et al,. Duration of immunosuppressive therapy in autoimmune hepatitis. J Hepatol 2001; 34: 354-5.
45. Kanzler S, Lohr H, Gerken G, et al,. Long-term management and prognosis of autoimmune hepatitis (AIH): a single center experience. Z Gastroenterol 2001; 39: 339-41. 44-8.
46. Ohana M, Hajiro K, Okazaki K, et al,. Clinical subgroup of autoimmune hepatitis type 1 sustaining remission without additional drugs. Hepatogastroenterology 1998; 45: 1667-72.
47. Yokokawa J, Kanno Y, Saito H, et al,. Risk factors associated with relapse of type 1 autoimmune hepatitis in Japan. Hepatol Res 2011; 41: 641-6.
48. Czaja AJ, Carpenter HA,. Histological features associated with relapse after corticosteroid withdrawal in type 1 autoimmune hepatitis. Liver Int 2003; 23: 116-23.
49. Czaja AJ, Wolf AM, Baggenstoss AH,. Laboratory assessment of severe chronic active liver disease during and after corticosteroid therapy: correlation of serum transaminase and gamma globulin levels with histologic features. Gastroenterology 1981; 80: 687-92.
50. Davis GL, Czaja AJ, Ludwig J,. Development and prognosis of histologic cirrhosis in corticosteroid-treated hepatitis B surface antigen-negative chronic active hepatitis. Gastroenterology 1984; 87: 1222-7.
51. Dhaliwal HK, Anderson R, Thornhill EL, et al,. Clinical significance of azathioprine metabolites for the maintenance of remission in autoimmune hepatitis. Hepatology 2012; 56: 1401-8.
52. Miyake Y, Iwasaki Y, Terada R, et al,. Persistent elevation of serum alanine aminotransferase levels leads to poor survival and hepatocellular carcinoma development in type 1 autoimmune hepatitis. Aliment Pharmacol Ther 2006; 24: 1197-205.
53. Longhi MS, Ma Y, Mieli-Vergani G, et al,. Aetiopathogenesis of autoimmune hepatitis. J Autoimmun 2010; 34: 7-14.
54. Czaja AJ, Manns MP,. Advances in the diagnosis, pathogenesis and management of autoimmune hepatitis. Gastroenterology 2010; 139: 58-72.
55. Bogdanos DP, Choudhuri K, Vergani D,. Molecular mimicry and autoimmune liver disease: virtuous intentions, malign consequences. Liver 2001; 21: 225-32.
56. Vergani D, Choudhuri K, Bogdanos DP, et al,. Pathogenesis of autoimmune hepatitis. Clin Liver Dis 2002; 6: 727-37.
57. Christen U, von Herrath MG,. Induction, acceleration or prevention of autoimmunity by molecular mimicry. Mol Immunol 2004; 40: 1113-20.
58. Doherty DG, Penzotti JE, Koelle DM, et al,. Structural basis of specificity and degeneracy of T cell recognition: pluriallelic restriction of T cell responses to a peptide antigen involves both specific and promiscuous interactions between the T cell receptor, peptide, and HLA-DR. J Immunol 1998; 161: 3527-35.
59. Kammer AR, van der Burg SH, Grabscheid B, et al,. Molecular mimicry of human cytochrome P450 by hepatitis C virus at the level of cytotoxic T cell recognition. J Exp Med 1999; 190: 169-76.
60. Albert LJ, Inman RD,. Molecular mimicry and autoimmunity. N Engl J Med 1999; 341: 2068-74.
61. Bittencourt PL, Farias AQ, Porta G, et al,. Frequency of concurrent autoimmune disorders in patients with autoimmune hepatitis: effect of age, gender, and genetic background. J Clin Gastroenterol 2008; 42: 300-5.
62. Efe C, Wahlin S, Ozaslan E, et al,. Autoimmune hepatitis/primary biliary cirrhosis overlap syndrome and associated extrahepatic autoimmune diseases. Eur J Gastroenterol Hepatol 2012; 24: 531-4.
63. Christen U, Hintermann E, Holdener M, et al,. Viral triggers for autoimmunity: is the 'glass of molecular mimicry' half full or half empty? J Autoimmun 2010; 34: 38-44.
64. Ma Y, Bogdanos DP, Hussain MJ, et al,. Polyclonal T-cell responses to cytochrome P450IID6 are associated with disease activity in autoimmune hepatitis type 2. Gastroenterology 2006; 130: 868-82.
65. Lee EY, Lee ZH, Song YW,. CXCL10 and autoimmune diseases. Autoimmun Rev 2009; 8: 379-83.
66. Trivedi PJ, Adams DH,. Mucosal immunity in liver autoimmunity: a comprehensive review. J Autoimmun 2013; 46: 97-111.
67. Antonelli A, Ferrari SM, Giuggioli D, et al,. Chemokine (C-X-C motif) ligand (CXCL)10 in autoimmune diseases. Autoimmun Rev 2014; 13: 272-80.
68. Czaja AJ, Carpenter HA,. Distinctive clinical phenotype and treatment outcome of type 1 autoimmune hepatitis in the elderly. Hepatology 2006; 43: 532-8.
69. Czaja AJ,. Clinical features, differential diagnosis and treatment of autoimmune hepatitis in the elderly. Drugs Aging 2008; 25: 219-39.
70. Currie MS,. Immunosenescence. Compr Ther 1992; 18: 26-34.
71. Donaldson PT, Doherty DG, Hayllar KM, et al,. Susceptibility to autoimmune chronic active hepatitis: human leukocyte antigens DR4 and A1-B8-DR3 are independent risk factors. Hepatology 1991; 13: 701-6.
72. Strettell MD, Donaldson PT, Thomson LJ, et al,. Allelic basis for HLA-encoded susceptibility to type 1 autoimmune hepatitis. Gastroenterology 1997; 112: 2028-35.
73. Czaja AJ, Strettell MD, Thomson LJ, et al,. Associations between alleles of the major histocompatibility complex and type 1 autoimmune hepatitis. Hepatology 1997; 25: 317-23.
74. Fainboim L, Marcos Y, Pando M, et al,. Chronic active autoimmune hepatitis in children. Strong association with a particular HLA-DR6 (DRB1 1301) haplotype. Hum Immunol 1994; 41: 146-50.
75. Pando M, Larriba J, Fernandez GC, et al,. Pediatric and adult forms of type I autoimmune hepatitis in Argentina: evidence for differential genetic predisposition. Hepatology 1999; 30: 1374-80.
76. Goldberg AC, Bittencourt PL, Mougin B, et al,. Analysis of HLA haplotypes in autoimmune hepatitis type 1: identifying the major susceptibility locus. Hum Immunol 2001; 62: 165-9.
77. Czaja AJ, Souto EO, Bittencourt PL, et al,. Clinical distinctions and pathogenic implications of type 1 autoimmune hepatitis in Brazil and the United States. J Hepatol 2002; 37: 302-8.
78. Vento S, Garofano T, Di Perri G, et al,. Identification of hepatitis A virus as a trigger for autoimmune chronic hepatitis type 1 in susceptible individuals. Lancet 1991; 337: 1183-7.
79. Huppertz HI, Treichel U, Gassel AM, et al,. Autoimmune hepatitis following hepatitis A virus infection. J Hepatol 1995; 23: 204-8.
80. Tanaka H, Tujioka H, Ueda H, et al,. Autoimmune hepatitis triggered by acute hepatitis A. World J Gastroenterol 2005; 11: 6069-71.
81. Tabak F, Ozdemir F, Tabak O, et al,. Autoimmune hepatitis induced by the prolonged hepatitis A virus infection. Ann Hepatol 2008; 7: 177-9.
82. Laskus T, Slusarczyk J,. Autoimmune chronic active hepatitis developing after acute type B hepatitis. Dig Dis Sci 1989; 34: 1294-7.
83. Vento S, Cainelli F, Renzini C, et al,. Autoimmune hepatitis type 2 induced by HCV and persisting after viral clearance. Lancet 1997; 350: 1298-9.
84. Robertson DA, Zhang SL, Guy EC, et al,. Persistent measles virus genome in autoimmune chronic active hepatitis. Lancet 1987; 2: 9-11.
85. Kojima K, Nagayama R, Hirama S, et al,. Epstein-Barr virus infection resembling autoimmune hepatitis with lactate dehydrogenase and alkaline phosphatase anomaly. J Gastroenterol 1999; 34: 706-12.
86. Kerkar N, Choudhuri K, Ma Y, et al,. Cytochrome P4502D6(193-212): a new immunodominant epitope and target of virus/self cross-reactivity in liver kidney microsomal autoantibody type 1-positive liver disease. J Immunol 2003; 170: 1481-9.
87. Gueguen M, Boniface O, Bernard O, et al,. Identification of the main epitope on human cytochrome P450 IID6 recognized by anti-liver kidney microsome antibody. J Autoimmun 1991; 4: 607-15.
88. Anand AC, Nagpal AK, Seth AK, et al,. Should one vaccinate patients with chronic liver disease for hepatitis A virus in India? J Assoc Physicians India 2004; 52: 785-7.
89. Worns MA, Teufel A, Kanzler S, et al,. Incidence of HAV and HBV infections and vaccination rates in patients with autoimmune liver diseases. Am J Gastroenterol 2008; 103: 138-46.
90. McNally RJ, James PW, Ducker S, et al,. Seasonal variation in the patient diagnosis of primary biliary cirrhosis: further evidence for an environmental component to etiology. Hepatology 2011; 54: 2099-103.
91. Bjornsson E, Talwalkar J, Treeprasertsuk S, et al,. Drug-induced autoimmune hepatitis: clinical characteristics and prognosis. Hepatology 2010; 51: 2040-8.
92. Czaja AJ,. Drug-induced autoimmune-like hepatitis. Dig Dis Sci 2011; 56: 958-76.
93. Bjornsson ES, Bergmann OM, Bjornsson HK, et al,. Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland. Gastroenterology 2013; 144: 1419-25.
94. Chicz RM, Urban RG, Gorga JC, et al,. Specificity and promiscuity among naturally processed peptides bound to HLA-DR alleles. J Exp Med 1993; 178: 27-47.
95. Derbinski J, Schulte A, Kyewski B, et al,. Promiscuous gene expression in medullary thymic epithelial cells mirrors the peripheral self. Nat Immunol 2001; 2: 1032-9.
96. Rosen A, Casciola-Rosen L,. Autoantigens in systemic autoimmunity: critical partner in pathogenesis. J Intern Med 2009; 265: 625-31.
97. Degen WG, Pruijn GJ, Raats JM, et al,. Caspase-dependent cleavage of nucleic acids. Cell Death Differ 2000; 7: 616-27.
98. Zampieri S, Degen W, Ghiradello A, et al,. Dephosphorylation of autoantigenic ribosomal P proteins during Fas-L induced apoptosis: a possible trigger for the development of the autoimmune response in patients with systemic lupus erythematosus. Ann Rheum Dis 2001; 60: 72-6.
99. Greidinger EL, Foecking MF, Ranatunga S, et al,. Apoptotic U1-70 kd is antigenically distinct from the intact form of the U1-70-kd molecule. Arthritis Rheum 2002; 46: 1264-9.
100. Dieker JW, Fransen JH, van Bavel CC, et al,. Apoptosis-induced acetylation of histones is pathogenic in systemic lupus erythematosus. Arthritis Rheum 2007; 56: 1921-33.
101. Berg CP, Stein GM, Keppeler H, et al,. Apoptosis-associated antigens recognized by autoantibodies in patients with the autoimmune liver disease primary biliary cirrhosis. Apoptosis 2008; 13: 63-75.
102. Hof D, Cheung K, de Rooij DJ, et al,. Autoantibodies specific for apoptotic U1-70K are superior serological markers for mixed connective tissue disease. Arthritis Res Ther 2005; 7: R302-9.
103. Grader-Beck T, Casciola-Rosen L, Lang TJ, et al,. Apoptotic splenocytes drive the autoimmune response to poly(ADP-ribose) polymerase 1 in a murine model of lupus. J Immunol 2007; 178: 95-102.
104. Sprent J,. Lifespans of naive, memory and effector lymphocytes. Curr Opin Immunol 1993; 5: 433-8.
105. McLean AR, Michie CA,. In vivo estimates of division and death rates of human T lymphocytes. Proc Natl Acad Sci USA 1995; 92: 3707-11.
106. Umeki S, Kusunoki Y, Cologne JB, et al,. Lifespan of human memory T-cells in the absence of T-cell receptor expression. Immunol Lett 1998; 62: 99-104.
107. Gray D, Skarvall H,. B-cell memory is short-lived in the absence of antigen. Nature 1988; 336: 70-3.
108. Obhrai JS, Oberbarnscheidt MH, Hand TW, et al,. Effector T cell differentiation and memory T cell maintenance outside secondary lymphoid organs. J Immunol 2006; 176: 4051-8.
109. Bell EB, Westermann J,. CD4 memory T cells on trial: immunological memory without a memory T cell. Trends Immunol 2008; 29: 405-11.
110. Ciruelo E, de la Cruz J, Lopez I, et al,. Cumulative rate of relapse of lupus nephritis after successful treatment with cyclophosphamide. Arthritis Rheum 1996; 39: 2028-34.
111. Bethoux F, Miller DM, Kinkel RP,. Recovery following acute exacerbations of multiple sclerosis: from impairment to quality of life. Mult Scler 2001; 7: 137-42.
112. Czaja AJ,. Autoimmune hepatitis after liver transplantation and other lessons of self-intolerance. Liver Transpl 2002; 8: 505-13.
113. Czaja AJ,. Recurrent autoimmune hepatitis after liver transplantation: a disease continuum or a fresh start? Liver Transpl 2009; 15: 1169-71.
114. Karlmark KR, Wasmuth HE, Trautwein C, et al,. Chemokine-directed immune cell infiltration in acute and chronic liver disease. Expert Rev Gastroenterol Hepatol 2008; 2: 233-42.
115. Wasmuth HE, Tacke F, Trautwein C,. Chemokines in liver inflammation and fibrosis. Sem Liver Dis 2010; 30: 215-25.
116. Manousou P, Kolios G, Drygiannakis I, et al,. CXCR3 axis in patients with primary biliary cirrhosis: a possible novel mechanism of the effect of ursodeoxycholic acid. Clin Exp Immunol 2013; 172: 9-15.
117. Cole KE, Strick CA, Paradis TJ, et al,. Interferon-inducible T cell alpha chemoattractant (I-TAC): a novel non-ELR CXC chemokine with potent activity on activated T cells through selective high affinity binding to CXCR3. J Exp Med 1998; 187: 2009-21.
118. Iwamoto S, Kido M, Aoki N, et al,. TNF-alpha is essential in the induction of fatal autoimmune hepatitis in mice through upregulation of hepatic CCL20 expression. Clin Immunol 2013; 146: 15-25.
119. Terada R, Yamamoto K, Hakoda T, et al,. Stromal cell-derived factor-1 from biliary epithelial cells recruits CXCR4-positive cells: implications for inflammatory liver diseases. Lab Invest 2003; 83: 665-72.
120. Isse K, Harada K, Zen Y, et al,. Fractalkine and CX3CR1 are involved in the recruitment of intraepithelial lymphocytes of intrahepatic bile ducts. Hepatology 2005; 41: 506-16.
121. Saeki C, Nakano M, Takahashi H, et al,. Accumulation of functional regulatory T cells in actively inflamed liver in mouse dendritic cell-based autoimmune hepatic inflammation. Clin Immunol 2010; 135: 156-66.
122. Doherty DG, Donaldson PT, Underhill JA, et al,. Allelic sequence variation in the HLA class II genes and proteins in patients with autoimmune hepatitis. Hepatology 1994; 19: 609-15.
123. Czaja AJ, Donaldson PT,. Genetic susceptibilities for immune expression and liver cell injury in autoimmune hepatitis. Immunol Rev 2000; 174: 250-9.
124. Czaja AJ, Doherty DG, Donaldson PT,. Genetic bases of autoimmune hepatitis. Dig Dis Sci 2002; 47: 2139-50.
125. Murasko DM, Goonewardene IM,. T-cell function in aging: mechanisms of decline. Annu Rev Gerontol Geriatr 1990; 10: 71-96.
126. Czaja AJ,. Rapidity of treatment response and outcome in type 1 autoimmune hepatitis. J Hepatol 2009; 51: 161-7.
127. Villanueva JL, Solana R, Alonso MC, et al,. Changes in the expression of HLA-class II antigens on peripheral blood monocytes from aged humans. Dis Markers 1990; 8: 85-91.
128. Schwab R, Russo C, Weksler ME,. Altered major histocompatibility complex-restricted antigen recognition by T cells from elderly humans. Eur J Immunol 1992; 22: 2989-93.
129. De Paoli P, Battistin S, Santini GF,. Age-related changes in human lymphocyte subsets: progressive reduction of the CD4 CD45R (suppressor inducer) population. Clin Immunol Immunopathol 1988; 48: 290-6.
130. Talor E, Rose NR,. Hypothesis: the aging paradox and autoimmune disease. Autoimmunity 1991; 8: 245-9.
131. Ben-Yehuda A, Weksler ME,. Immune senescence: mechanisms and clinical implications. Cancer Invest 1992; 10: 525-31.
132. Chen J, Eslick GD, Weltman M,. Systematic review with meta-analysis: clinical manifestations and management of autoimmune hepatitis in the elderly. Aliment Pharmacol Ther 2014; 39: 117-24.
133. Cookson S, Constantini PK, Clare M, et al,. Frequency and nature of cytokine gene polymorphisms in type 1 autoimmune hepatitis. Hepatology 1999; 30: 851-6.
134. Czaja AJ, Cookson S, Constantini PK, et al,. Cytokine polymorphisms associated with clinical features and treatment outcome in type 1 autoimmune hepatitis. Gastroenterology 1999; 117: 645-52.
135. Agarwal K, Czaja AJ, Jones DE, et al,. Cytotoxic T lymphocyte antigen-4 (CTLA-4) gene polymorphisms and susceptibility to type 1 autoimmune hepatitis. Hepatology 2000; 31: 49-53.
136. Hiraide A, Imazeki F, Yokosuka O, et al,. Fas polymorphisms influence susceptibility to autoimmune hepatitis. Am J Gastroenterol 2005; 100: 1322-9.
137. Agarwal K, Czaja AJ, Donaldson PT,. A functional Fas promoter polymorphism is associated with a severe phenotype in type 1 autoimmune hepatitis characterized by early development of cirrhosis. Tissue Antigens 2007; 69: 227-35.
138. Bittencourt PL, Palacios SA, Cancado EL, et al,. Autoimmune hepatitis in Brazilian patients is not linked to tumor necrosis factor alpha polymorphisms at position -308. J Hepatol 2001; 35: 24-8.
139. Bittencourt PL, Palacios SA, Cancado EL, et al,. Cytotoxic T lymphocyte antigen-4 gene polymorphisms do not confer susceptibility to autoimmune hepatitis types 1 and 2 in Brazil. Am J Gastroenterol 2003; 98: 1616-20.
140. Schott E, Witt H, Pascu M, et al,. Association of CTLA4 single nucleotide polymorphisms with viral but not autoimmune liver disease. Eur J Gastroenterol Hepatol 2007; 19: 947-51.
141. Umemura T, Ota M, Yoshizawa K, et al,. Association of cytotoxic T-lymphocyte antigen 4 gene polymorphisms with type 1 autoimmune hepatitis in Japanese. Hepatol Res 2008; 38: 689-95.
142. Fan LY, Tu XQ, Zhu Y, et al,. Genetic association of cytokines polymorphisms with autoimmune hepatitis and primary biliary cirrhosis in the Chinese. World J Gastroenterol 2005; 11: 2768-72.
143. Paladino N, Flores AC, Fainboim H, et al,. The most severe forms of type I autoimmune hepatitis are associated with genetically determined levels of TGF-beta1. Clin Immunol 2010; 134: 305-12.
144. Vogel A, Strassburg CP, Manns MP,. Genetic association of vitamin D receptor polymorphisms with primary biliary cirrhosis and autoimmune hepatitis. Hepatology 2002; 35: 126-31.
145. Vogel A, Strassburg CP, Manns MP,. 77 C/G mutation in the tyrosine phosphatase CD45 gene and autoimmune hepatitis: evidence for a genetic link. Genes Immun 2003; 4: 79-81.
146. Esteghamat F, Noorinayer B, Sanati MH, et al,. C77G mutation in protein tyrosine phosphatase CD45 gene and autoimmune hepatitis. Hepatol Res 2005; 32: 154-7.
147. Fan L, Tu X, Zhu Y, et al,. Genetic association of vitamin D receptor polymorphisms with autoimmune hepatitis and primary biliary cirrhosis in the Chinese. J Gastroenterol Hepatol 2005; 20: 249-55.
148. Campbell DJ, Kim CH, Butcher EC,. Chemokines in the systemic organization of immunity. Immunol Rev 2003; 195: 58-71.
149. Moreno C, Gustot T, Nicaise C, et al,. CCR5 deficiency exacerbates T-cell-mediated hepatitis in mice. Hepatology 2005; 42: 854-62.
150. Heydtmann M, Lalor PF, Eksteen JA, et al,. CXC chemokine ligand 16 promotes integrin-mediated adhesion of liver-infiltrating lymphocytes to cholangiocytes and hepatocytes within the inflamed human liver. J Immunol 2005; 174: 1055-62.
151. Mistilis SP, Skyring AP, Blackburn CR,. Natural history of active chronic hepatitis. I. Clinical features, course, diagnostic criteria, morbidity, mortality and survival. Australas Ann Med 1968; 17: 214-23.
152. De Groote J, Fevery J, Lepoutre L,. Long-term follow-up of chronic active hepatitis of moderate severity. Gut 1978; 19: 510-3.
153. Feld JJ, Dinh H, Arenovich T, et al,. Autoimmune hepatitis: effect of symptoms and cirrhosis on natural history and outcome. Hepatology 2005; 42: 53-62.
154. Kogan J, Safadi R, Ashur Y, et al,. Prognosis of symptomatic versus asymptomatic autoimmune hepatitis: a study of 68 patients. J Clin Gastroenterol 2002; 35: 75-81.
155. Manns MP, Czaja AJ, Gorham JD, et al,. Diagnosis and management of autoimmune hepatitis. Hepatology 2010; 51: 2193-213.
156. Gleeson D, Heneghan MA,. British Society of Gastroenterology (BSG) guidelines for management of autoimmune hepatitis. Gut 2011; 60: 1611-29.
157. Montano-Loza AJ, Carpenter HA, Czaja AJ,. Features associated with treatment failure in type 1 autoimmune hepatitis and predictive value of the model of end-stage liver disease. Hepatology 2007; 46: 1138-45.
158. Yeoman AD, Westbrook RH, Zen Y, et al,. Early predictors of corticosteroid treatment failure in icteric presentations of autoimmune hepatitis. Hepatology 2011; 53: 926-34.
159. Selvarajah V, Montano-Loza AJ, Czaja AJ,. Systematic review: managing suboptimal treatment responses in autoimmune hepatitis with conventional and nonstandard drugs. Aliment Pharmacol Ther 2012; 36: 691-707.
160. Burak KW, Swain MG, Santodomino-Garzon T, et al,. Rituximab for the treatment of patients with autoimmune hepatitis who are refractory or intolerant to standard therapy. Can J Gastroenterol 2013; 27: 273-80.
161. Weiler-Normann C, Schramm C, Quaas A, et al,. Infliximab as a rescue treatment in difficult-to-treat autoimmune hepatitis. J Hepatol 2013; 58: 529-34.
162. Lapierre P, Beland K, Yang R, et al,. Adoptive transfer of ex vivo expanded regulatory T cells in an autoimmune hepatitis murine model restores peripheral tolerance. Hepatology 2013; 57: 217-27.
163. Dhirapong A, Yang GX, Nadler S, et al,. Therapeutic effect of cytotoxic T lymphocyte antigen 4/immunoglobulin on a murine model of primary biliary cirrhosis. Hepatology 2013; 57: 708-15.
164. Zachou K, Dalekos GN,. Hepatitis B re-activation with rituximab therapy: treat the patient not the disease. Liver Int 2011; 31: 277-9.
165. Saitis A, Gatselis N, Zachou K, et al,. Use of TNFalpha antagonists in refractory AIH: revealing the unforeseen. J Hepatol 2013; 59: 197-8.
166. Czaja AJ,. Advances in the current treatment of autoimmune hepatitis. Dig Dis Sci 2012; 57: 1996-2010.
167. Czaja AJ, Carpenter HA, Santrach PJ, et al,. Significance of HLA DR4 in type 1 autoimmune hepatitis. Gastroenterology 1993; 105: 1502-7.
168. Czaja AJ, Rakela J, Ludwig J,. Features reflective of early prognosis in corticosteroid-treated severe autoimmune chronic active hepatitis. Gastroenterology 1988; 95: 448-53.
169. Rosenkrantz JG, Githens JH, Cox SM, et al,. Azathioprine (Imuran) and pregnancy. Am J Obstet Gynecol 1967; 97: 387-94.
170. Klieger-Grossmann C, Chitayat D, Lavign S, et al,. Prenatal exposure to mycophenolate mofetil: an updated estimate. J Obstet Gynaecol Can 2010; 32: 794-7.
171. Perez-Aytes A, Ledo A, Boso V, et al,. In utero exposure to mycophenolate mofetil: a characteristic phenotype? Am J Med Genet A 2008; 146A: 1-7.